AbbVie Inc (ABBV) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
AbbVie Inc stock (ABBV) is currently trading at $207.18. AbbVie Inc PE ratio is 86.95. AbbVie Inc PS ratio (Price-to-Sales) is 5.93. Analyst consensus price target for ABBV is $249.14. WallStSmart rates ABBV as Hold.
AbbVie Inc (ABBV) stock price prediction for 2030: Base case $64.41. Bull case $80.51. Bear case $48.31. See full ABBV 2030 price forecast and methodology on WallStSmart.
- ABBV PE ratio analysis and historical PE chart
- ABBV PS ratio (Price-to-Sales) history and trend
- ABBV intrinsic value — DCF, Graham Number, EPV models
- ABBV stock price prediction 2025 2026 2027 2028 2029 2030
- ABBV fair value vs current price
- ABBV insider transactions and insider buying
- Is ABBV undervalued or overvalued?
- AbbVie Inc financial analysis — revenue, earnings, cash flow
- ABBV Piotroski F-Score and Altman Z-Score
- ABBV analyst price target and Smart Rating
AbbVie Inc
📊 No data available
Try selecting a different time range
ABBV Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · AbbVie Inc (ABBV)
ABBV trades 1191% above its Graham fair value of $16.05, indicating the stock may be overvalued at current levels.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
AbbVie Inc (ABBV) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in market cap, peg ratio, return on equity. Concerns around price/book and eps growth. Fundamentals are solid but monitor weak areas for improvement.
AbbVie Inc (ABBV) Key Strengths (5)
Mega-cap company, among the largest in the world
Growing significantly faster than its price suggests
Every $100 of shareholder equity generates $62 in profit
Keeps $34 of every $100 in revenue after operating costs
76.41% of shares held by major funds and institutions
Supporting Valuation Data
AbbVie Inc (ABBV) Areas to Watch (5)
Earnings declining -88.70%, profits shrinking
Very expensive at 50.5x book value
Premium valuation at 5.9x annual revenue
Thin profit margins with limited profitability
Solid revenue growth at 10.00% per year
Supporting Valuation Data
AbbVie Inc (ABBV) Detailed Analysis Report
Overall Assessment
This company scores 63/100 in our Smart Analysis, earning a C+ grade. Out of 10 metrics analyzed, 5 register as strengths (avg 10.0/10) while 5 fall into concern territory (avg 3.2/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Market Cap, PEG Ratio, Return on Equity. Valuation metrics including PEG Ratio (0.49) suggest the stock is attractively priced. Profitability is solid with Return on Equity at 62.30%, Operating Margin at 34.10%.
The Bear Case
The primary concerns are EPS Growth, Price/Book, Price/Sales. Some valuation metrics including Price/Sales (5.93), Price/Book (50.46) suggest expensive pricing. Growth concerns include Revenue Growth at 10.00%, EPS Growth at -88.70%, which may limit upside. Profitability pressure is visible in Profit Margin at 6.91%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether EPS Growth improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 62.30% currently healthy but needing to be sustained. Third, growth sustainability, with Revenue Growth at 10.00% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a moderate-to-high risk investment. Strengths and concerns are roughly balanced. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Mixed fundamentals with both positives (Market Cap, PEG Ratio) and negatives (EPS Growth, Price/Book). A cautious approach is warranted. Monitor for improvement in weak areas before increasing conviction.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
ABBV Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
ABBV's Price-to-Sales ratio of 5.93x trades at a 26% premium to its historical average of 4.69x (87th percentile). The current valuation is 15% below its historical high of 7x set in Jan 2018, and 98% above its historical low of 2.99x in Aug 2019.
WallStSmart Analysis Synopsis
Data-driven financial summary for AbbVie Inc (ABBV) · HEALTHCARE › DRUG MANUFACTURERS - GENERAL
The Big Picture
AbbVie Inc operates as a stable business with moderate growth and solid fundamentals. Revenue reached 61.2B with 10% growth year-over-year. Profit margins are thin at 6.9%, typical for companies in this phase that are reinvesting heavily in growth.
Key Findings
ROE of 62.3% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
Generating 4.9B in free cash flow and 5.2B in operating cash flow. Earnings are translating into actual cash generation.
What to Watch Next
Margin expansion: can AbbVie Inc push profit margins above 15% as the business scales?
Valuation compression risk at a P/E of 87.0x. Any growth miss could trigger a sharp correction.
Dividend sustainability with a current yield of 3.3%. Watch payout ratio and free cash flow coverage.
Debt management: total debt of 68.9B is significantly higher than cash (5.2B). Monitor refinancing risk.
Bottom Line
AbbVie Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(67 last 3 months)
| Insider | Type | Shares |
|---|---|---|
PURDUE, DAVID RYAN SVP, Controller | Sell | -5,230 |
Data sourced from SEC Form 4 filings
Last updated: 2:34:39 PM
About AbbVie Inc(ABBV)
NYSE
HEALTHCARE
DRUG MANUFACTURERS - GENERAL
USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.